Rallentamento dell'invecchiamento e futuro della sanità nel mondo digitale

Quali possono essere le cause dell'invecchiamento, la medicina preventiva del futuro e i potenziali strumenti che possono aiutare le persone a vivere più a lungo, ad avere un impatto e a combattere l'invecchiamento nel mondo digitale? Nella conversazione tra il Dr. David Sinclair, Professore di Genetica e co-direttore del Paul F. Glenn Center for the Biology of Aging della Harvard Medical School, che è stato incluso nella lista delle "100 persone più influenti al mondo" della rivista TIME Magazine e nella "Top 50 people in Healthcare"; e, è diventato Ufficiale dell'Ordine dell'Australia nel 2018; e, Boris G. Tsimerinov, CEO, Semper8. 



Dr. David Sinclair

Professor of Genetics and co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School

David A. Sinclair, Ph.D., A.O. is a Professor in the Department of Genetics, Blavatnik Insitute, and co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. He is best known for his work on understanding why we age and how to slow its effects. He obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney, in 1995 and did his postdoctoral research at M.I.T. with Dr. Leonard Guarente where he co discovered a cause of aging for yeast as well as the role of Sir2 in epigenetic changes driven by genome instability and aging. In 1999 he moved to Harvard Medical School and has primarily focused on understanding why we age and the role of protective enzymes called the sirtuins, which respond to changing NAD+ levels, exercise, and caloric restriction (CR). The Sinclair lab was the first to identify a role for NAD biosynthesis in the regulation of lifespan and first showed that sirtuins are involved in CR’s benefits in mammals and identified the first small molecules that activate SIRT1 (STACs). His lab is currently focusing on epigenetic changes as a driver of aging and the use of reprogramming factors to reset the age of cells and tissues. He is the New York Times bestselling author of Lifespan (2019), has published over 200 scientific papers, is a co-inventor on over 50 patents, and has co-founded biotechnology companies in the areas of aging, vaccines, diabetes, fertility, cancer, and biodefense. He serves as co-chief editor of the scientific journal Aging and has received 35 honors including the Australian Medical Research Medal, the Irving Wright Award, the NIH Director’s Pioneer award, TIME magazine’s list of the “100 most influential people in the world” and the “Top 50 people in Healthcare”. In 2018, he became an Officer of the Order of Australia (AO).

Boris Tsimerinov


Boris Tsimerinov leads Semper8 which currently consists of interconnected Semper8 Capital (an investment and advisory firm conducting family office private equity & VC investments; M&A and advisory projects; and, restructurings); Semper8 Health (start-up group, investment and advisory practice focused on healthcare; biotech; digital health; medical devices; and related sectors) and Semper8 Media (start-up group, investment and advisory practice focused on developing inclusive, innovative and thought-provoking content). He is also a global speaker, writer and educator.

Organizzatore principale

Partner Principale